Group A Streptococcus (GAS), an exclusively human pathogen, causes a wide range of diseases ranging from trivial to life threatening. Treatment of infection is often ineffective following entry of bacteria into the bloodstream. To date, there is no vaccine available against GAS. In this study, cationic liposomes encapsulating lipopeptide-based vaccine candidates against GAS have been employed for intranasal vaccine delivery. Cationic liposomes were prepared with dimethyldioctadecylammonium bromide (DDAB) using the film hydration method. Female Swiss mice were immunized intranasally with the liposomes. In contrast to unmodified peptides, lipopeptides entrapped by liposomes induced both mucosal and systemic immunity, IgA and IgG (IgG1 and IgG2a) production in mice, respectively. High levels of antibody (IgA and IgG) titres were detected even five months post immunization.
Introduction
Group A Streptococcus (GAS), also known as Streptococcus pyogenes, is a gram positive bacterium, which infects more than 600 million people each year [1] contributing to millions of dollars in healthcare expenditure. Clinical manifestations of GAS infections such as pharyngitis or impetigo, are typically self-limiting [2] .
However, if left untreated, the disease can progress to an invasive state which may lead to life threatening diseases such as necrotizing fasciitis and streptococcal toxic shock syndrome (STSS) [3, 4] . Carapetis et al. estimated the number of invasive GAS (iGAS) disease cases exceeds half a million annually [1] . Approximately 20% of patients with iGAS disease die within a week of infection [5, 6] . The mortality rate increases by 25% if the patient develops STSS. Although these diseases are of special concern, GAS mortality is mainly associated with rheumatic heart diseases (RHD) and rheumatic fever (RF). It has been estimated that 19 million people suffer from RHD and the annual death toll approximates 470 000 worldwide [7] .
The main route of GAS infection is through direct contact of bacteria with the mucosal membrane [6, 8] . Courtney et al. demonstrated that the binding of GAS to substratum involves the M protein [9] . The M protein is a major virulence factor of GAS, which is expressed by all pathogenic strains. Apart from functioning as an adhesin, the M protein has an antiphagocytic property to increase bacterial survival in the host [10] . This alpha-helical coiled dimer protein comprises four distinct repeat regions (A to D) that have varying percentages of conservation [9, 11] . M protein is hypervariable at the N-terminal where there are more than 250 known emm-serotypes whereas its C-repeat region is highly conserved [11] .
Protected individuals' express IgG antibodies, which are reactive to the M protein, making this protein the perfect target for vaccine development. However, the full length M protein contains sequences similar to human cardiac tissues; therefore, it is not feasible to utilize the whole protein as a vaccine antigen [12] . Massell et al. showed that some patients developed rheumatic fever following vaccination with type 3 streptococcal M protein [13] . Hence, peptides derived from M protein rather than whole protein have been used as a safe alternative for vaccine development against GAS. Hayman et al. described minimal antigenic epitopes, J8 and J14 from the M protein [14] . These epitopes have formed the basis of a number of vaccine studies to induce systemic and mucosal immunity [15] .
M protein epitope-based GAS vaccine candidates were reported to induce strong systemic humoral immunity (i.e. production of IgG) [16, 17] . However, GAS typically colonizes the epithelia of the osopharynx; thus, the induction of mucosal immunity [production of secretory IgA (sIgA)] is required as a primary barrier, protecting mucosal surfaces from colonization by the bacteria [18] .
Recently, we have designed and synthesised a library of vaccine candidates bearing the J14 peptide sequence (KQAEDKVKASREAKKQVEKALEQLEDKVK), a conserved B-cell epitope derived from the M protein of GAS and P25 (KLIPNASLIENCTKAEL), a universal T-helper epitope. The epitopes were incorporated into the lipid core peptide (LCP), a self-adjuvanting carrier system which combines peptide epitopes, branching moiety (e.g. lysine) and lipoamino acid into one molecule. LCP has been extensively used as a peptide-based vaccine delivery system and showed high efficacy to stimulate immune responses against hookworm [19, 20] , malaria [21] , Schistosoma [20, 22] and cancer [23] . While the majority of reported LCP conjugates induced strong systemic responses, only lipopeptide 1 ( Figure 1 ) was able to induce mucosal immunity [24] . This compound also stimulated systemic immune responses in mice model [24, 25, 26] and was able to activate toll like receptor 2 [27] . In order to further improve the efficacy of this vaccine candidate, we incorporated 1, and newly designed lipopeptides bearing the same epitopes, into cationic liposomes (Figure 1b) . These liposomes stimulated high levels of IgG and IgA titres even five months following final immunization.
Experimental Section

Materials
All chemical materials used in this study were analytical grade unless otherwise nm. Analytical RP-HPLC was performed using an Agilent (Agilent 1100 series) instrument with a 1 mL/min flow rate and detection at 214 nm. Following synthesis, the peptide-resin was washed thrice with DMF, dichloromethane (DCM) and methanol before overnight drying in a desiccator. The peptide was cleaved from the resin using a cocktail of trifluoroacetic acid (TFA):triisopropylsilane (TIS):water (95:2.5:2.5). TFA was removed under reduced pressure and peptide was precipitated with cold diethyl ether. The peptide precipitate was subsequently dissolved in acetonitrile/water (50:50) prior to lyophilization. J14 was purified using Shimadzu preparative RP-HPLC on the C18 Vydac column with a solvent gradient of 0-50%, 10 mL/min solvent B (90% acetonitrile, 10% Milli Q water, 0.1% TFA).
Methods
Peptide
Analytical HPLC analysis was performed using the C18 column (Grace): t R = 18.7 min, purity > 98%. ESI 
Lipopeptide synthesis
Lipopeptides 1-5 were synthesised using tert-butyloxycarbonyl (Boc) SPPS. The peptides were synthesised on a 0.2 mmol scale using MBHA resin. Coupling reagents used to activate and couple the amino acids were the same as those in the Fmoc synthesis. Microwave-assisted Boc SPPS was carried out by using a SPS mode CEM Discovery reactor. Each amino acid was coupled twice, 1 x 5 min and 1 x 10 min at 70 °C with DMF washes in between. Deprotection of the Boc group was achieved using TFA, 2 x 1 min with stirring at room temperature. Fmoc side-chain protected lysine was used for branching in order to attach both epitopes, J14 and P25. The Fmoc group was removed using 20% piperidine. Hydrofluoric acid (HF) was used to cleave the peptides from the resin. HF cleavage (10 mL HF/g resin) was performed at -8 °C in the presence of 5% (v/v) p-cresol and 5% (v/v) p-thiocresol.
Lipopeptide 1
Lipopeptide 1 was purified using preparative Shimadzu RP-HPLC on the C4 Vydac column with a solvent gradient of 55-80% solvent B. Analytical HPLC analysis was performed using Agilent instrument (C4 column): t R = 27.9 min, purity > 95%. ESI- 
Formulation of liposome vaccine constructs
All lipids (DPPC, DDAB and cholesterol) were dissolved in chloroform prior to formulation; DPPC:DDAB:Chol in a molar ratio of 5:2:1. Chloroform was slowly evaporated under slightly reduced pressure with the help of rotatory evaporator.
Residual chloroform was removed under vacuum overnight. Antigen was dissolved in sterile Milli Q water prior to hydration of the lipid film. Liposomes were formulated using lipid hydration method [29] at 56 °C prior to extrusion with a 0.1 µm PC membrane.
Liposomal Characterization
Liposomal size was measured by photon correlation spectroscopy using a Zetasizer 3000 TM (Malvern Instruments, Malvern, UK). To calculate loading efficacy, a predetermined amount of antigen was encapsulated into liposomes, which were then pelleted by ultracentrifugation (Beckman TLA100.2 rotor at 100 000 rpm X 1 hr).
The supernatant was removed prior lysing with methanol. The amount of antigen was measured against a known standard curve using an ultraviolet-visible spectroscopy (UV-Vis) at wavelength 214 nm.
Transmission electron microscopy
Liposomal samples were prepared as mentioned above. Following extrusion, samples were diluted 10X before fixing to carbon-coated 200 mesh grid. Excess liposomal formulation was removed after three minutes. Pictures were taken using JEM-1010 transmission electron microscope (JOEL Ltd., Japan).
Cell uptake studies
Samples were processed under sterile conditions. Murine spleens kept in DMEM buffer were transferred onto a 70 µm strainer and mashed. The cell strainer was washed with complete IMDM buffer (IMDM Glutamax medium supplemented with 10% FBS, 50 µM 2-mercaptoethanol, 100 U/mL penicillin, and 100 µg/mL streptomycin) and centrifuged at 400 g for 10 minutes. The supernatant was discarded and the pellet resuspended in 1 mL of erylysis buffer and incubated for seven minutes.
Cells were stained with tryphan blue and counted using the haemocytometer. Cells were seeded at a density of 1 X 10 6 cells/well and incubated for two hours at 37 °C in a 5% CO 2 incubator. Liposomes stained with Dil were added to each well and incubated overnight at 37 °C in a 5 % CO 2 incubator. Cells were scraped and centrifuged at 400 g for 10 minutes. The supernatant was discarded. Fc-blocker 
Immunological assessment
All animal protocols were approved by the Institute's ethics committee (Griffifth For long-term immunological study, unvaccinated (v(-)) and mice previously immunized with L1 were stimulated with L1, 10 µL/nare at day 186 post primary immunization. 
Collection of serum and saliva
Determination of antibody titres by ELISA
An enzyme-linked immunosorbent assay (ELISA) was performed to measure J14-specific serum IgG, including IgG1 and IgG2a isotypes, and IgA titres. Statistical significance (p<0.05) was determined using one-way ANOVA with Tukey post hoc test for determination of J14-specific IgG and IgA titres.
Results
Synthesis and characterization
Boc-and Fmoc-SPPS were applied for the synthesis of compounds 1-5. Resultant compounds were purified and incorporated into liposomes. Liposomes were formulated using cationic lipid (DDAB), DPPC and cholesterol by the lipid hydration method. Liposomes were characterized for size, surface charge and morphology using dynamic light scattering (DLS) and transmission electron microscopy (TEM) ( Table   1 , Figure 2 ). 
Cell uptake studies
Dendritic cells and macrophages account for the majority of the antigen-presenting cells (APCs), which are responsible for initiating the adaptive immune responses.
Liposomal uptake studies were evaluated using murine CD11c + dendritic cells and F4/80 + macrophages. There was no significant difference in uptake of L1-L4 by dendritic cells and macrophages.
Immunogenicity of liposomal vaccine candidates
Female Swiss mice were intranasally immunized on day 0 with 20 µL (10 µL/nare) of 
L1-L4
Discussion
Liposomes are widely used for drug and vaccine delivery, thanks to its invaluable properties of being biocompatible and biodegradable while concurrently increasing potency and reducing the toxicity of delivered agents [30] . Other advantages of using liposomes as a delivery system include its ability to entrap relatively large amounts of antigen while protecting the antigen from degradation. Liposomes composed of DPPC, DDAB and cholesterol, were formulated to encapsulate antigens with moderate to high encapsulation efficacy. The high encapsulation was observed for lipidated peptides due to their ability to anchor into the lipidic layer through their lipidic tails [31] . Size analysis by DLS and TEM ( Figure 2) showed that LCP-loaded liposomes vaccines were approximately 200 nm in diameter. Nanoparticles between 20-200 nm have been known to easily travel to lymph nodes and be preferentially endocytosed by dendritic cells [32] . Other properties of liposomes (e.g. charge) were also reported to have an influence on their recognition by APCs [33] . However, the changes of entrapped antigens (P25, J14, 1-5) did not affect uptake of liposomes by
APCs as shown in Figure 3 . This lack of differentiation can be explained by similar surface charges and size of the liposomes irrespective of entrapped antigens (L1-L4, Table 1 ) [34] .
Systemic IgG antibodies are needed to prevent septicaemia in the circulatory system which leads to invasive GAS sequelae. However, a vaccine that is also able to produce mucosal IgA is beneficial in order to prevent colonization of GAS in the mucosa lining and to prevent entry of bacteria into the circulatory system [35] . Mice immunized with L4 gave the highest J14-specific systemic and mucosal antibody titres which were higher than those induced by mice immunized with peptide antigens adjuvanted with strong but toxic CTB adjuvant (control) (Figure 4 J14 and P25 to the same cell, which is crucial, as J14 peptide alone is unlikely to induce strong antibody titres in an outbred population due to its small size. Moreover, incorporation of lipidated peptide into liposomes was able to induce IgG titres that were stronger than the positive control adjuvanted with CTB.
Conclusion
In this study, we have investigated the use of cationic liposomes together with lipopeptide antigens as vaccine candidates against GAS. 
